Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction
Cardiovascular Research · 2023
DOI: 10.1093/cvr/cvad078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2023. Verfasst von Maria Vistnes und 21 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Kirkeveien 166, 0450 Oslo, Norway. Hauptthemen laut MEDLINE: Heart Failure, Cardiomyopathies. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SPARK, Norwegian Health Association, Novo Nordisk Pioneer Grant.
Abstract (Originalsprache)
Aims
Heart failure is a condition with high mortality rates, and there is a lack of therapies that directly target maladaptive changes in the extracellular matrix (ECM), such as fibrosis. We investigated whether the ECM enzyme known as A disintegrin and metalloprotease with thrombospondin motif (ADAMTS) 4 might serve as a therapeutic target in treatment of heart failure and cardiac fibrosis. Methods and results The effects of pharmacological ADAMTS4 inhibition on cardiac function and fibrosis were examined in rats exposed to cardiac pressure overload. Disease mechanisms affected by the treatment were identified based on changes in the myocardial transcriptome. Following aortic banding, rats receiving an ADAMTS inhibitor, with high inhibitory capacity for ADAMTS4, showed substantially better cardiac function than vehicle-treated rats, including ∼30% reduction in E/e′ and left atrial diameter, indicating an improvement in diastolic function. ADAMTS inhibition also resulted in a marked reduction in myocardial collagen content and a down-regulation of transforming growth factor (TGF)-β target genes. The mechanism for the beneficial effects of ADAMTS inhibition was further studied in cultured human cardiac fibroblasts producing mature ECM. ADAMTS4 caused a 50% increase in the TGF-β levels in the medium. Simultaneously, ADAMTS4 elicited a not previously known cleavage of TGF-β-binding proteins, i.e. latent-binding protein of TGF-β and extra domain A-fibronectin. These effects were abolished by the ADAMTS inhibitor. In failing human hearts, we observed a marked increase in ADAMTS4 expression and cleavage activity.
Conclusion
Inhibition of ADAMTS4 improves cardiac function and reduces collagen accumulation in rats with cardiac pressure overload, possibly through a not previously known cleavage of molecules that control TGF-β availability. Targeting ADAMTS4 may serve as a novel strategy in heart failure treatment, in particular, in heart failure with fibrosis and diastolic dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.
- K.G. Jebsen Center for Cardiac Research, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.
- Department of Cardiology, Oslo University Hospital Ullevål, Kirkeveien 166, 0450 Oslo, Norway.
- Department of Internal Medicine, Diakonhjemmet Hospital, Diakonveien 12, 0370 Oslo, Norway.
- Research Institute of Internal Medicine, Oslo University Hospital and University of Oslo, Sognsvannsveien 20, 0372 Oslo, Norway.
- Department of Oncology, Oslo University Hospital, Ullernchausseen 70, 0379 Oslo, Norway.
ORCID-Profile: Maria Vistnes, Ivar Sjaastad, Geir Christensen
Förderung
- SPARK
- Norwegian Health Association
- Novo Nordisk Pioneer Grant
- South-Eastern Health Authorities
- Promotion of Science, Simon Fougner Hartmann’s Family Fund
- Rakel and Otto-Kristian Bruuns Endowment
Zitieren
APA
Vistnes, M., Erusappan, P. M., Sasi, A., Nordén, E. S., Bergo, K. K., Romaine, A., Lunde, I. G., Zhang, L., Olsen, M. B., Øgaard, J., Carlson, C. R., Wang, C. H., Riise, J., Dahl, C. P., Fiane, A. E., Hauge-Iversen, I. M., Espe, E., Melleby, A. O., Tønnessen, T., …, & Christensen, G. (2023). Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction. Cardiovascular Research. https://doi.org/10.1093/cvr/cvad078
Vancouver
Vistnes M, Erusappan PM, Sasi A, Nordén ES, Bergo KK, Romaine A, et al. Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction. Cardiovascular Research. 2023. doi:10.1093/cvr/cvad078
BibTeX
@article{Vistnes2023,
author = {Vistnes, Maria and Erusappan, Pugazendhi Murugan and Sasi, Athiramol and Nordén, Einar Sjaastad and Bergo, Kaja Knudsen and Romaine, Andreas and Lunde, Ida Gjervold and Zhang, Lili and Olsen, Maria Belland and Øgaard, Jonas and Carlson, Cathrine Rein and Wang, Christian Hjorth and Riise, Jon and Dahl, Christen Peder and Fiane, Arnt Eltvedt and Hauge-Iversen, Ida Marie and Espe, Emil and Melleby, Arne Olav and Tønnessen, Theis and Aronsen, Jan Magnus and Sjaastad, Ivar and Christensen, Geir},
title = {Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction},
journal = {Cardiovascular Research},
year = {2023},
doi = {10.1093/cvr/cvad078}
}
EUVIMED